Page 1,519«..1020..1,5181,5191,5201,521..1,5301,540..»

Biotechnology | USDA

Posted: May 1, 2017 at 4:42 am

Advances in science, many of them from scientists at USDA or through research funded by USDA, have opened up new options for farmers responding to market needs and environmental challenges. Many new plant varieties being developed or grown by farmers have been produced using genetic engineering, which involves manipulating the plant's genes through techniques of modern molecular biology often referred to as recombinant DNA technology. These techniques are included in what is often referred to as "biotechnology" or "modern biotechnology."

USDA supports the safe and appropriate use of science and technology, including biotechnology, to help meet agricultural challenges and consumer needs of the 21st century. USDA plays a key role in assuring that biotechnology plants and products derived from these plants are safe to be grown and used in the United States. Once these plants and products enter commerce, USDA supports bringing these and other products to the worldwide marketplace.

Three federal agencies are involved in ensuring that plants produced using biotechnology and the many products derived from them are safe for farmers to use, safe to consume as food or feed, and safe for the environment. These are USDA's Animal and Plant Health Inspection Service, the Department of Health and Human Services' Food and Drug Administration, and the United States Environmental Protection Agency. The three agencies regulate these products based on the characteristics of the actual products and their intended uses, and they operate under the existing laws passed by Congress to ensure the safety of plants used in agriculture, the safety of pesticides used in agriculture, and the safety of foods we eat and feeds given to animals. Many other USDA agencies have roles in the development, use, and marketing of these products as well.

Learn more about How the U.S. Government Regulates Biotech Plants.

Since the first successful commercialization of a biotechnology-derived crop in the 1990s, many new crop varieties have been developed and made available to U.S. farmers and farmers worldwide. U.S. farmers have rapidly adopted many of these new GE varieties, so that in 2012, 88 percent of the corn, 94 percent of the cotton, and 93 percent of the soybeans planted in the U.S. were varieties produced through genetic engineering. A large proportion of the production of other crops, such as alfalfa, and papaya, and sugar beet, is also biotech-derived.

Read more about the reasons behind this trend and about how farming practices and the marketplace have changed on USDA's Economic Research Service Biotechnology page.

The United States is the largest exporter of agricultural products, which helps feed the world's population, and our export markets are critical to the health of U.S. farm communities around the country. Most of the corn and soybeans we export are biotechnology-derived, and this means that working with our trading partners is critical to help them understand the technical aspects of new products and how we have determined that they meet our high safety standards, to open up new markets, and to ensure that our products are treated fairly in the global marketplace.

The increasing use of biotechnology in agriculture has changed, and will continue to change, farming and the work of USDA in the long-term. To help understand and address these changes, USDA established the Advisory Committee on Biotechnology and 21st Century Agriculture (AC21). One critical area where the committee has focused its attention is how farmers who produce different crops intended for different customers-biotechnology-derived, conventional, or organic-can best co-exist and produce the crops that meet their customers' needs. The AC21 has provided a report to USDA, with recommendations, on this subject.

Visit the AC21 page to learn more.

Here is the original post:
Biotechnology | USDA

Posted in Biotechnology | Comments Off on Biotechnology | USDA

Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of … – The Cerbat Gem

Posted: May 1, 2017 at 4:42 am


The USA Commerce
Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of ...
The Cerbat Gem
Puma Biotechnology logo Equities analysts expect that Puma Biotechnology Inc (NYSE:PBYI) will announce earnings per share (EPS) of ($2.08) for the current ...
Focusing the Lens on Puma Biotechnology, Inc. (NASDAQ:PBYI ...Rives Journal
Stock Jumping Abnormally High: Puma Biotechnology, Inc. (PBYI)HugoPress
Brokerage Firm Analysts Consensus on Puma Biotechnology, Inc ...Midway Monitor
Concord Register -The USA Commerce
all 8 news articles »

More here:
Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of ... - The Cerbat Gem

Posted in Biotechnology | Comments Off on Puma Biotechnology Inc (PBYI) Expected to Announce Earnings of … – The Cerbat Gem

3SBio: Is this Chinese Biotechnology Stock a Buy? – Barron’s (blog)

Posted: May 1, 2017 at 4:42 am

By Isabella Zhong

Shenyang-based 3SBio (1530.HK) is a biopharmaceutical pioneer that offers a unique play on Chinas rising demand for healthcare.

The company is best known for its rheumatoid arthritis drug YSP, which accounts for 33% of revenues, and TPIAO, a hormone used in the treatment of platelet deficiencies.

While YSP and TPIAO are expected to deliver strong sales growth in coming years, a recent price cut for anemia drug EPIAO and limited R&D upside in the near term could weigh on 3SBio. Jefferies analyst Eugene Huang initiated coverage of the stock today with a hold rating and an HKD11.50 a share target price, which implies 11% upside.

Huang has more on 3SBios drugs pipeline:

3SBios HER2 (breast cancer) and CD20 (lymphoma) candidates were withdrawn, leaving peers like Fosun potentially to become FTM generics. Besides, we factored in Rmb20/50/110m 17/18/19E sales from Bydureon (exenatide ER, GLP-1, diabetes), which is pending NDA approval. We are concerned there might be a lack of synergy between 3SBio and AstraZenecas diabetes team as well as integration risks.

Shares of 3SBio are up 37% this year and trade at 23 times forward earnings, which is in line with its five year average. Analysts surveyed by FactSet expect 3SBio to grow earnings at a 28.3% average annual pace over the next three to five years. While the stocks scarcity value and long-term growth potential look appealing, investors may want to wait for a better entry point.

Continued here:
3SBio: Is this Chinese Biotechnology Stock a Buy? - Barron's (blog)

Posted in Biotechnology | Comments Off on 3SBio: Is this Chinese Biotechnology Stock a Buy? – Barron’s (blog)

Endothelial progenitor cell – Wikipedia

Posted: May 1, 2017 at 4:41 am

Endothelial progenitor cell (or EPC) is a term that has been applied to multiple different cell types that play roles in the regeneration of the endothelial lining of blood vessels. Outgrowth endothelial cells are an EPC subtype committed to endothelial cell formation.[1] Despite the history and controversy, the EPC in all its forms remains a promising target of regenerative medicine research.

Developmentally, the endothelium arises in close contact with the hematopoietic system. This, and the existence of hemogenic endothelium, led to a belief and search for adult hemangioblast- or angioblast-like cells; cells which could give rise to functional vasculature in adults.[2] The existence of endothelial progenitor cells has been posited since the mid-twentieth century, however their existence was not confirmed until the 1990s when Asahara et al. published the discovery of the first putative EPC.[3]

Recently, controversy has developed over the definition of true endothelial progenitors.[4] Although bone marrow-derived cells do appear to localize to injured vessels and promote an angiogenic switch, other studies have suggested these cells do not contribute directly to the functional endothelium, instead acting via paracrine methods to provide support for the resident endothelial cells.[5][6] While some other authors have contested these, and maintained that they are true EPCs,[7] many investigators have begun to term these cells colony forming unit-Hill cells (CFU-Hill) or circulating angiogenic cells (CAC) instead (depending on the method of isolation), highlighting their role as hematopoietic myeloid cells involved in promoting new vessel growth.[8][9]

Molecular genetic analysis of early outgrowth putative EPC populations suggests they do indeed have monocyte-like expression patterns, and support the existence of a separate population of progenitors, the late outgrowth, or endothelial colony forming cell (ECFC).[10] Furthermore, early outgrowth cells maintain other monocyte functions such as high Dil-Ac-LDL and India ink uptake and low eNOS expression. These original, early outgrowth, CFU-Hill or CACs are also shown to express CD14, a lipopolysaccharide receptor expressed by monocytes but not endothelial cells.[11]

Endothelial colony forming cells represent a distinct population that has been found to have the potential to differentiate and promote vessel repair. ECFCs are now known to be tissue-resident progenitor cells in adults that maintain some vasculogenic ability.[12]

By method of isolation and cell function, three main populations of putative adult EPCs have been described. The behavior of the cells can be found in the following table.[9][13]

EPCs also have variable phenotypic markers used for identification. Unfortunately, there are no unique markers for endothelial progenitors that are not shared with other endothelial or hematopoietic cells, which has contributed to the historical controversy surrounding the field. A detailed overview of current markers can be found in the following table.[2][13]

As originally isolated by Asahara et al., the CFU-Hill population is an early outgrowth, formed by plating peripheral blood mononuclear cells on fibronectin-coated dishes, allowing adhesion and depleting non-adherent cells, and isolating discrete colonies.[8][9]

A similar method is to culture the peripheral blood mononuclear fraction in supplemented endothelial growth medium, removing the non-adherent cells, and isolating the remaining. While these cells display some endothelial characteristics, they do not form colonies.[8][9]

Endothelial colony forming cells are a late outgrowth cell type; that is, they are only isolated after significantly longer culture than CFU-Hill cells. ECFCs are isolated by plating peripheral blood mononuclear fraction on collagen-coated plates, removing non-adherent cells, and culturing for weeks until the emergence of colonies with a distinctive cobblestone morphology. These cells are phenotypically similar to endothelial cells and have been shown to create vessel-like structures in vitro and in vivo.[8][9]

Certain developmental cells may be similar to or the same as other endothelial progenitors, though not typically referred to as EPCs. Hemangioblasts (or their in vitro counterpart, blast - colony forming cells) are cells believed to give rise to both the endothelial and hematopoietic systems during early development. Angioblasts are believed to be a form of early progenitor or stem cell which gives rise to the endothelium alone. More recently, mesoangioblasts have been theorized as a cell giving rise to multiple mesodermal tissues.[14][15][16]

Endothelial progenitor cells are likely important in tumour growth and are thought to be critical for metastasis and the angiogenesis.[17][18] A large amount of research has been done on CFU-Hill bone marrow-derived putative EPCs. Ablation of the endothelial progenitor cells in the bone marrow lead to a significant decrease in tumour growth and vasculature development. This indicates that endothelial progenitor cells present novel therapeutic targets.[19]Inhibitor of DNA Binding 1 (ID1) has been used as a marker for these cells;[20] this allows for tracking EPCs from the bone marrow to the blood to the tumour-stroma and even incorporated in tumour vasculature.

Recently it has been found that miRNAs regulate EPC biology and tumour angiogenesis. This work by Plummer et al. found that in particular targeting of the miRNAs miR-10b and miR-196b led to significant defects in angiogenesis-mediated tumor growth by decreasing the mobilization of proangiogenic EPCs to the tumour. These findings indicate that directed targeting these miRNAs in EPCs may result in a novel strategy for inhibiting tumor angiogenesis.[21]

Studies have shown ECFCs and human umbilical vein endothelial cells (HUVECs) to have a capacity for tumor migration and neoangiogenesis even greater than that of other CD34+ hematopoietic cells when implanted in immunodeficient mice, suggesting the endothelial progenitors play a key role, but further supporting the importance of both cell types as targets for pharmacological therapy.[22]

Higher levels of circulating "endothelial progenitor cells" were detected in the bloodstream of patients, predicted better outcomes, and patients experienced fewer repeat heart attacks,[23] though statistical correlations between these outcomes and circulating endothelial progenitor cell numbers were scant in the original research. Endothelial progenitor cells are mobilized after a myocardial infarction, and that they function to restore the lining of blood vessels that are damaged during the heart attack.

A number of small phase clinical trials have begun to point to EPCs as a potential treatment for various cardiovascular diseases (CVDs). For instance, the year long "Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction" (TOPCARE-AMI) studied the therapeutic effect of infusing ex-vivo expanded bone marrow EPCs and culture enriched EPCs derived from peripheral blood into 20 patients suffering from acute myocardial infarction (MI). After four months, significant enhancements were found in ventricular ejection fraction, cardiac geometry, coronary blood flow reserve, and myocardial viability (Shantsila, Watson, & Lip). A similar study looked at the therapeutic effects of EPCs on leg ischemia caused by severe peripheral artery disease. The study injected a sample of EPC rich blood into the gastrocnemius muscles of 25 patients. After 24 weeks an increased number of collateral vessels and improved recovery in blood perfusion was observed. Rest pain and pain-free walking were also noted to have improved [24]

The role of endothelial progenitor cells in wound healing remains unclear. Blood vessels have been seen entering ischemic tissue in a process driven by mechanically forced ingress of existing capillaries into the avascular region, and importantly, instead of through sprouting angiogenesis. These observations contradict sprouting angiogenesis driven by EPCs. Taken together with the inability to find bone-marrow derived endothelium in new vasculature, there is now little material support for postnatal vasculogenesis. Instead, angiogenesis is likely driven by a process of physical force.[25]

In endometriosis, it appears that up to 37% of the microvascular endothelium of the ectopic endometrial tissue originates from endothelial progenitor cells.[26]

Read more here:
Endothelial progenitor cell - Wikipedia

Posted in Cell Medicine | Comments Off on Endothelial progenitor cell – Wikipedia

Stem cell therapy ‘magic’ for stroke, eye ailments – Vanguard News – Vanguard

Posted: May 1, 2017 at 4:41 am

By David Ikudayisi

In recently published papers in the New England Journal of Medicine about the use of Stem Cell Therapy for Macular Degeneration, one report showed that 3 partially blind women became blind after the treatment with stem cells and the other report showed that an inevitable loss of vision was halted by use of stem cells in another patient. The stem cells used in these two reports were from two different sources fat and skin cells.

First of all, we need to remember or understand that Macular Degeneration is caused by the deterioration of the central portion of the retina, known as the macula, and it is responsible for focusing central vision in the eye, and it controls our ability to read, drive a car, recognize faces or colors, and see objects in fine detail. In America, it affects more than 10 million people more than cataracts and glaucoma combined.

Caucasians are more likely to develop the disease than African-Americans, Hispanics/Latinos or Africans. At present, Macular Degeneration is considered an incurable eye disease, and the closest hope for cure seems to be via Stem Cell Therapy. As shown in the reports, there is still a lot to be understood about stem cells in terms of dosing, frequency, source to be used for different disorders, etc; especially when talking about very sensitive organs of the body like the eyes.

The Florida Company that treated the three patients that went from partial blindness to total blindness have treated over 7,000 patients and have had very few adverse events reported. The scientific director of the company believes the safety track record is very strong and feels very confident about the procedures that they do as it has shown great success in many different health problems.

However, the rarity of the procedure causing harm draws me to see the many benefits and potential Adult Stem Cell Therapy could have on people. Examples of its effectiveness has been seen in so many patients in different studies and even in my own practice in the United States of America. There are already beneficiaries of Adult Stem Cell Therapy in Nigeria. I can say that my experience using stem cells have been great.

In fact, of all the patients that I have treated, only one did not respond positively after just 1 treatment. This was not even done with Adult Stem Cell Therapy but Platelet Rich Plasma (PRP) Therapy using the patients own blood. Nevertheless, there was no adverse event. The patient is recommended to do Adult Stem Cell Therapy which will increase his chance of success. Many of the other patients showed improvements after the first treatment, and the few that needed second treatment went on to see amazing results after more treatment was done; needless to say that they were elated with the results.

Generally, Adult Stem Cell Therapy and Platelet Rich Plasma Therapy are safe as shown by many published research reports and clinical trials done already. However, this does not guarantee that adverse effects cant occur as seen in the case of the 3 women who had accelerated blindness 2 years ago (as with any other treatments in the scope of medicine).

Another recent report in March 2017 from Medical College of Georgia at Augusta University in USA highlighted one of the benefits of Adult Stem Cell Therapy in stroke patients. The multicenter trial shows that not only was it safe, but if Adult Stem Cell Therapy is given within two days of an ischemic stroke, it could reduce the death of cells around the strokes core that were also injured. The Nigerian government should get involved more and invest more in Regenerative Medicine as it will help improve the health status of the nation.

Continue reading here:
Stem cell therapy 'magic' for stroke, eye ailments - Vanguard News - Vanguard

Posted in Cell Therapy | Comments Off on Stem cell therapy ‘magic’ for stroke, eye ailments – Vanguard News – Vanguard

Griffin to host talk on diabetes, foot health – Connecticut Post – CT Post

Posted: May 1, 2017 at 4:40 am

Photo: Contributed / Contributed

The Diabetes Education & Support Group at Griffin Hospital will host a free presentations on diabetes medication on Tuesday, May 9 at 2:30 p.m. Photo courtesy of Griffin Hospital.

The Diabetes Education & Support Group at Griffin Hospital will host a free presentations on diabetes medication on Tuesday, May 9 at 2:30 p.m. Photo courtesy of Griffin Hospital.

Griffin to host talk on diabetes, foot health

DERBY The Diabetes Education & Support Group at Griffin Hospital will host a free presentations on foot health on Tuesday, May 9 at 2:30 p.m. at the hospital, 130 Division St., Derby.

Podiatrist Dr. Luke Jeffries, of Yale Podiatry Group, will present Foot Care & Prevention of Foot Complications in the hospitals Childbirth Education Classroom A. There is free valet parking.

The Diabetes Education & Support Group meets September through June on the second Tuesday of each month to discuss the management of diabetes, its challenges, and day-to-day dietary concerns. Individuals with diabetes and their caregivers are welcome to attend.

No registration is required. For more information, call Mary Swansiger at 203-732-1137.

Excerpt from:
Griffin to host talk on diabetes, foot health - Connecticut Post - CT Post

Posted in Diabetes | Comments Off on Griffin to host talk on diabetes, foot health – Connecticut Post – CT Post

Closing the Diabetes Disparities Gap – Huffington Post

Posted: May 1, 2017 at 4:40 am

When it comes to diabetes in the United States, minority populations are hardest hit.

African Americans and Hispanics are almost twice as likely as non-Hispanic whites to be diagnosed with diabetes by a physician, according to the U.S. Department of Health and Human Services Office of Minority Health and national examination surveys. African American and Hispanic Americans have higher rates of end-stage renal disease (ESRD) caused by diabetes and start ESRD treatment 2.4 and 1.6 times more often, respectively, compared with non-Hispanic whites.

Income, stable and affordable housing, access to healthy food, quality education and a host of other factors influence a person's health status and longevity. These factors, what public health professionals recognize as social determinants of health, contribute to higher rates of diabetes and associated illness in African American and Hispanic American communities.

During National Minority Health Month each April, the U.S. Department of Health and Human Services Office of Minority Health (OMH) leads the nation in raising awareness about these disparities, their causes and the impact they have on minority communities and the nation as a whole.

The theme of this years National Minority Health Month observance Bridging Health Equity Across Communities, emphasizes the collaborative, community-level work being done across the

nation to help achieve health equity. Dannons partnership with WIC and Lenox Hill Hospitals partnership with leading health providers are two examples of collaborative efforts to bridge the health equity gap.

One way Dannon is helping to achieve health in minorities is by working to make healthier food choices readily available to WIC participants. The addition of yogurt to the WIC food packages, which began on April 1, 2015, brings important nutrients to pregnant women, breastfeeding mothers and young children at critical life stages.

Yogurt is especially well suited for the WIC audience. Most yogurts provide three out of the four nutrients of concern -- calcium, potassium and vitamin D -- and eating yogurt regularly is associated with less weight gain over time. Overweight and obesity are two major risk factors for diabetes. Yogurt is also a source of high quality protein, which can help support bone and muscle strength, and most yogurts contain live and active cultures that help with lactose digestion.

Dannon offers a variety of WIC eligible products to meet WIC participants needs and preferences which can be found here.

Lenox Hill Hospital Partnership

The Gerald J. Friedman Diabetes Institute at Lenox Hill Hospital in New York along with a coalition of other leading health care providers, government officials, public- and private-sector companies, and community-based organizations, recently pledge to help build a sustainable path to health and wellness for the thousands of New Yorkers living with diabetes.

The coalitions new program Vida SI, Diabetes NO! (Life YES! Diabetes NO!), is a bilingual, long-term health initiative that will take a comprehensive and systematic look at diabetes among Latinos with the goal of uncovering the root causes, leading to more effective and efficient delivery of prevention, education, testing, and treatment.

Participants of Vida SI, Diabetes NO! (Life YES! Diabetes NO!) have access to bi-lingual diabetes educators, nutritionists, social workers, exercise trainers and other diabetes specialists to help improve the management of their diabetes and help them live longer healthier lives.

You can learn more about Vida SI, Diabetes NO! (Life YES, Diabetes NO!) on social media including Facebook https://www.facebook.com/VidaSIDiabetesNO on https://twitter.com/VSIDNO and on Instagram under user name @vsidno.

Dannons partnership with WIC and Lenox Hills Vida SI, Diabetes NO! (Life YES! Diabetes NO!) program are national and community level partnerships that will help close the diabetes disparities gap in African Americans and Hispanics.

More here:
Closing the Diabetes Disparities Gap - Huffington Post

Posted in Diabetes | Comments Off on Closing the Diabetes Disparities Gap – Huffington Post

Diabetes, weight gain can alter your brain, says study – WLWT Cincinnati

Posted: May 1, 2017 at 4:40 am

(CNN)

It's well-known that type 2 diabetes can cause medical complications in certain organs, including the brain. But overweight and obese people with early-stage type 2 diabetes have more severe abnormalities in brain structure and cognition than normal-weight people with type 2 diabetes, according to a new study in Diabetologia, the journal of the European Association for the Study of Diabetes.

Having type 2 diabetes and being overweight, then, can combine to have a greater effect on brain structures.

"There's a general agreement that type 2 diabetes is a risk factor for various types of both structural and functional abnormalities in the brain," said Dr. Donald C. Simonson, a co-author of the study and an endocrinologist specializing in diabetes. "Simple obesity also shows the same type of abnormalities ... in a milder stage. You can see where it's not quite exactly normal but not quite as bad as someone with diabetes.

"So, if you have both, will it be worse than if you have them alone? That's what we looked at in this particular study," said Simonson, who teaches at Harvard's T.H. Chan School of Public Health.

Dr. In Kyoon Lyoo, lead author and a professor at the Ewha Brain Institute at Ewha Womens University in Seoul, South Korea, wrote in an email, "As obesity has been known to be associated with metabolic dysfunction, inflammation, and brain changes independently of diabetes, we expected that brain alterations might be more pronounced in overweight/obese participants with type 2 diabetes."

Effects on the brain

Lyoo, Simonson and their colleagues designed a study around 50 overweight or obese people age 30 to 60 who had been diagnosed with type 2 diabetes.

Fifty normal-weight people diagnosed with type 2 diabetes and 50 normal-weight people without diabetes also participated. These additional participants were age and sex matched to the original group. Those diagnosed with diabetes were also matched for disease duration. Standard body mass index ranges defined "overweight" (having a BMI of 25 to 29.9), "obese" (greater than 30) and "normal weight" (18.5 to 25).

The researchers used magnetic resonance imaging to examine each participant's brain structure, including the thickness of the cerebral cortex and white matter connectivity. Gray matter in the brain contains the neuron cell bodies, whereas white matter contains bundles of nerve fibers and its job is to process and send signals along the spinal cord.

The researchers chose to study thickness and connectivity "because these could be sensitive markers of diabetes-related brain changes, and could be reliably quantified by using magnetic resonance imaging," Lyoo explained.

Participants also were tested for memory, psychomotor speed and executive function, since these are known to be affected in people with type 2 diabetes.

The results aligned with the researchers' initial assumptions, Lyoo said.

Clusters of gray matter were significantly thinner in the temporal, prefrontoparietal, motor and occipital cortices in the brains of diabetic participants than in the non-diabetic group, the study found. More thinning of the temporal and motor cortices could be seen in the overweight/obese diabetic group compared with normal-weight diabetics. Separately and collectively, these areas of the brain impact motor control, executive function, body awareness, concentration and other cognitive functions.

"Most of the things we looked at, you could see that there was a progression, and the obese patients with diabetes were worse than the lean patients with diabetes, and they were both worse than the age-matched controls," Simonson said.

In particular, the temporal lobe appears vulnerable to the combined effects of type 2 diabetes and being overweight or obese, the researchers say. The temporal lobe is implicated in language comprehension and long-term memory.

The brain has been the last frontier in the study of complications of diabetes, Simonson said.

Similarities to Alzheimer's disease

"Diabetic retinopathy, eye disease, is reasonably well-understood," he said. "The same is true of kidney disease, amputations -- we understand much better what causes them and how to prevent them.

"But the brain has been the proverbial black box. It's incredibly complicated, and you can't directly study it. You can't go in and take samples," he said. "The last several years, the techniques of MRI got good enough that we could really look carefully at the brain."

Most of the initial work in the very late 1990s was done in Alzheimer's, schizophrenia, depression and other classic psychiatric diseases, but then scientists began to look at other diseases including diabetes, explained Simonson. At this point, researchers around the world began to see connections.

"You can see a person with depression has thinning of the surface of the brain in certain areas, and you go in and do the same study with somebody with diabetes, and they have thinning in the exact same areas," Simonson said. And diabetes may be a predisposing or risk factor for developing Alzheimer's, he said.

"You see the same types of abnormalities in a milder form in the brain in people with diabetes that you see in people with Alzheimer's disease," Simonson said.

According to Dr. William T. Cefalu, chief scientific, medical and mission officer of the American Diabetes Association, the study is consistent with previous research.

"The presence of overweight and obesity have been shown in other studies to be associated with early structural changes in the brain, and may contribute to cognitive issues," said Cefalu, who was not involved in the new study. "The current study implies that obesity/overweight status in individuals with diabetes may also contribute."

That said, longer-term and more definitive studies are needed to evaluate that aspect.

In the end, Simonson said, another question is more important: "What can you do to prevent it? That's the big question."

See the rest here:
Diabetes, weight gain can alter your brain, says study - WLWT Cincinnati

Posted in Diabetes | Comments Off on Diabetes, weight gain can alter your brain, says study – WLWT Cincinnati

UMD loses student athlete to diabetes-related complications – SouthCoastToday.com

Posted: May 1, 2017 at 4:40 am

Aimee Chiavaroli achiavaroli@s-t.com

UMASS DARTMOUTH A UMass Dartmouth male student and lacrosse player died Saturday due to complications related to Type 1 Diabetes, according to a news release.

Sean Peters was a Crime and Justice major and four-year member of the mens lacrosse team, according to the universitys athletics website. He was 22 years old and went to UMass Dartmouth from Medway High School.

Our hearts are broken by Seans passing, Interim Chancellor Peyton R. Helm wrote to students, faculty, and staff Saturday. There are no words that can adequately express the profound loss being felt today by his family, friends, teammates, and classmates. All we can do is hold close those who loved Sean and support them in the difficult days ahead.

We are deeply saddened by the loss of Sean, said Amanda Van Voorhis, athletic director, in a statement. Sean was a four-year letter winner for the Corsairs, and was in the midst of the most prolific season of his career. He had just been recognized on Senior Day last Saturday. This is incomprehensible and a tremendous loss for our athletic community. The UMass Dartmouth Athletics family extends our condolences to the Peters family and loved ones.

According to the news release, Peters was the epitome of a Corsair who balanced the challenging demands of being a student and an athlete.

Peters appeared in 49 career games, starting 24 and all 13 of his contests during his senior campaign. This year, he had 23 goals and 14 assists for 37 points. He registered four goals in a game twice this season, including a career-high seven-point performance in UMass Dartmouths 19-5 win over Becker College April 10. In his final game April 22, he tallied two goals and two assists versus Western Connecticut State University in a 14-8 win, according to the university.

"We encourage friends, teammates, and community members who were close to Sean, and there were many, to come together to support each other and his family at this most difficult time, said David Milstone, associate vice chancellor for student affairs, in a statement. We will ask the family if they are amenable to holding a campus memorial. Our counseling staff is available to meet with members of the community as individuals or as groups."

Read this article:
UMD loses student athlete to diabetes-related complications - SouthCoastToday.com

Posted in Diabetes | Comments Off on UMD loses student athlete to diabetes-related complications – SouthCoastToday.com

Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M – FinSMEs (blog)

Posted: April 29, 2017 at 5:51 pm


FinSMEs (blog)
Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M
FinSMEs (blog)
Paris, France based Advent France Biotechnology has held the first close of Advent France Biotechnology Seed-Fund I, at 64.75m (USD68.5m). Supported in by the National Seed-Fund (Fonds National d'Amorage) managed by Bpifrance under the ...

More here:
Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M - FinSMEs (blog)

Posted in Biotechnology | Comments Off on Advent France Biotechnology Holds First Close of Biotechnology Fund I, at 64.75M – FinSMEs (blog)

Page 1,519«..1020..1,5181,5191,5201,521..1,5301,540..»